Petah Tikva, Israel – Huntington’s disease is a rare, fatal neurodegenerative disease that is desperate for treatment options and doctors are doing their best to help improve the quality of life for the more than 30,000 people living with the disease and over 200,000 at-risk of inheriting the disease. Teva Pharmaceutical and Intel recently partnered to help bring a solution to this devastating disease.

Using a new cloud based monitoring system developed by Intel to wirelessly transfer data, Teva is creating a new wearable device that will deploy for the first time ever in the ongoing Phase 2 Open-Pride HD Study.

The aim of this important project is to provide continuous objective data on the impact of Huntington disease on the patient, and, by extension, a clear understanding of the impact of treatment on patients’ quality of life, said Michael Hayden, President of Teva Global R&D and Chief Scientific Officer.

Why this matters:

We continue to see the trend of wearable technology entering the healthcare market to improve patients’ lives and overall experiences. It is exciting to see, in the above example, wearable technology evolving into a practice that may one-day fuel new treatment options for a devastating disease such as Huntington’s. It is also great to see a cloud based monitoring platform in development with this project that could fuel new and exciting relationships between consumer wearables and seamlessly transferring health data to PCP’s to better overall health.

Article Credit – Sam Cannizzaro – SVP, Group Creative Director, GSW Newtown

About the Author:

As Strategist of Innovation, Drew is charged daily with championing innovative thinking and doing. Drew is part of a global team that leads new innovative ideas that attract different advocates among existing and potential brands that are shared across all agency partners. Drew is backed by over 16 years of brand, sales and marketing experience with Fortune 500 companies such as Progressive and Nationwide Insurance as well as Founder & President of his own healthcare insurance agency for 6 years. Most recently Drew was part of the agency team that launched Briviact for UCB, Foundation Medicine as well as key roles with Eli Lilly Oncology and Johnson & Johnson.